Ceramide mediates covid-19 vascular injury and ards

Ended Project Grant Awarded Last action

Award ID
W81XWH2210244
Recipient
Awarding agency
Obligated
$1,802,392

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
Denver, CO 80206, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The National Jewish Health will receive $1,802,392 from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to investigate ceramide's role in COVID-19 vascular injury and acute respiratory distress syndrome (ARDS) from September 30, 2022 through September 29, 2026. The goal of this Project Grant award is to transform health care for service members and the public through innovative biomedical research that seeks to understand how ceramide mediates vascular damage caused by COVID-19, with a focus on ARDS as a potentially lethal complication of the virus. Insights gained from this research may lead to new medical solutions for treating COVID-19 and its associated health impacts.

Quick answers

Who received award W81XWH2210244?

W81XWH2210244 was awarded to National Jewish Health by Medical Command (Department of the Army) on September 30, 2022.

How much is award W81XWH2210244 worth?

$1,802,392 has been obligated on W81XWH2210244.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login